tebu-bio is a European company specialised in providing innovative reagents and laboratory services in Life Sciences

Need an answer now?

Give us a call

Leave a message, we'll get back to you

CleanCap mRNA research updates

Latest Trilink RNA technology publication

Lipid Nanoparticle-encapsulated mRNA Vaccines Elicit Protective CD8 T Cells

Memory CD8 T cells have been shown to protect susceptible strains of mice from mousepox, a fatal disease caused by the ectromelia virus (ECTV). One way of inducing memory CD8 T cells is to immunize mice with dendritic cells that have been pulsed with small, ECTV-derived peptides. However, a main drawback of this approach is its complexity, highlighting the need for an alternative method that can be adapted for human use. Vaccines comprising modified mRNA encapsulated in lipid nanoparticles (LNP) are a leading strategy, especially following recent successes in tackling COVID-19, but the mechanisms by which these vaccines exert their effects remain unclear. In a study soon to publish in Molecular Therapy, Knudson et al. demonstrate that LNP-mRNA vaccines elicit memory CD8 T cells in a mouse model of smallpox to protect from lethal viral challenge. This finding has significance for other LNP-mRNA vaccines, including those against SARS-CoV-2.


Vaccines should Induce both protective antibodies and CD8 T cells

Vaccine efficacy is commonly evaluated in terms of the antibody response, yet this does not provide a complete picture. On their own, antibodies may not be sufficient for protection, largely because the epitopes they recognize are often highly mutable. For this reason, the antibody response is usually complemented by other immune mechanisms, including the production of memory CD8 T cells. Since individuals possessing memory CD8 T cells are typically better protected against infection compared to their naïve counterparts, it is important when developing vaccines to ensure they induce both protective antibodies and CD8 T cells.


Advantages of LNP-mRNA

Many established vaccines comprise an attenuated form of the pathogen, meaning they are generally capable of eliciting memory CD8 T cells. However, the complexity of developing such products precludes their deployment in a pandemic situation such as that presented by COVID-19. In contrast, designing and manufacturing LNP-mRNA vaccines is far simpler, as proven by the rapid development of effective vaccines against SARS-CoV-2. Further advantages of LNP-mRNA vaccines are that they are readily translated following cellular uptake, with no risk of integration into the genome, and contain fewer extraneous components that could generate an unwanted immune response. Researchers keen to leverage these benefits are now investigating how LNP-mRNA vaccines exert their effects.

LNP-mRNA vaccines elicit protective CD8 T cells

Having previously demonstrated that memory CD8 T cells induced by peptide-dendritic cell immunization protected mice against ECTV challenge, Knudson et al. used the same ECTV model to determine whether LNP-mRNA vaccines could provide the same protective effect. To achieve this, they immunized mice with LNPs containing different doses of unmodified or N(1)-methylpseudouridine-modified mRNA encoding the ECTV gene EVM158 and monitored the CD8 T cell response by flow cytometry. Although results were comparable for both types of mRNA, the unmodified form was found to produce adverse effects at the inoculation site. Critically, a single immunization with 10 µg of modified mRNA protected most susceptible mice from mousepox, while a booster vaccination increased the memory CD8 T cell pool to provide full protection.

TriLink’s products were used to prepare the modified mRNA for this study. After cloning the ECTV EVM158 gene into an mRNA production plasmid, the resulting mRNA was transcribed, then the uridine 5’-triphosphates were substituted for N(1)-methylpseudouridine 5’-triphosphates and the cap1 structure was generated using CleanCap. The purified mRNA was then encapsulated in LNPs for intramuscular injection.



Take a look at other CleanCap publications

Watch the latest Trilink webinars and videos on mRNA technlogy

mRNA sequence optimization is an important step in the design of mRNA vaccines and therapeutics. In this mRNA Basics webinar, Cory Smith, Senior Technical Inside Sales Specialist at TriLink, will walk through the strategies and resources for coding sequence optimization.

Multiple mRNA capping technologies are available today, each with advantages and disadvantages. In this mRNA Basics webinar, Scott Taylor, MS, Senior Alliance Manager at TriLink, will discuss common mRNA capping strategies and which applications they are best suited for. A live Q&A session will follow the presentation.

The innate immune response is critical to consider when designing your mRNA sequence and manufacturing process. In this mRNA Basics webinar, Cory Smith, Senior Technical Inside Sales Specialist at TriLink, will highlight several strategies for minimizing the innate immune response to mRNA therapeutics. A live Q&A session will follow the presentation.

In celebration of mRNA Day 2020, TriLink proudly presents back-to-back webinars by two pioneers of the mRNA therapeutic platform: Dr. Katalin Karikó (BioNTech) and Dr. Drew Weissman (University of Pennsylvania). Dr. Karikó provides an overview of the history of mRNA therapeutics, while Dr. Weissman offers his perspective on the future of mRNA medicines. A moderated Q&A session follows the presentations.

Don't miss this on tebu-bio's blog!

Want to know more about CleanCap?

Read this article on our blog to learn all about the CleanCap technology.


Download the CleanCap documentation

CleanCap technical brochure

Global CleanCap applications brochure